Seizures do not occur randomly in the majority of people with epilepsy. They tend to cluster. Seizure clusters, in turn, commonly occur with a temporal rhythmicity that shows a readily identifiable and predictable periodicity. When the periodicity of seizure exacerbation in women conforms to that of the menstrual cycle, it is commonly known as catamenial epilepsy. This may be attributable to 1) the neuroactive properties of steroid hormones and 2) the cyclic variation in their serum levels. If hormones play a role in seizure occurrence, hormones may also have a role in treatment. Progesterone has potent GABAergic metabolites that may provide safe and effective seizure control in women who have catamenial epilepsy.
INTRODUCTION
There are reasons to consider a role for hormones in the pathophysiology and treatment of epilepsy. Reproductive steroids have neuroactive properties that can modulate neuronal excitability. Cyclic variation in the serum concentrations of neuroactive steroids are associated with and may cause a variation in seizure occurrence during the menstrual cycle that is known as catamenial epilepsy. If hormones have a role in seizure occurrence, hormones may also have a role in treatment. By way of specific therapeutic consideration and application, progesterone is a reproductive steroid that has potent neuroactive GABAergic metabolites which show antiseizure effects in experimental animal models and may have utility in the management of seizures in women with catamenial epilepsy.
NEUROACTIVE PROPERTIES OF REPRODUCTIVE STEROIDS
There is considerable scientific evidence at the molecular biological, neuronal, experimental animal, and clinical levels of investigation to suggest that some reproductive steroids have neuroactive properties that may play an important role in the pathophysiology of epilepsy and patterns of seizure occurrence (FIG. 1) . Steroids act in the brain by short-latency, direct membrane-mediated effects, 1 as well as by long-latency, receptor-mediated, genomically transcribed and translated effects. 
Estradiol
Estradiol has complex, age-and sex-specific, doseand time-dependent effects on neuronal and synaptic transmission that can modulate neuronal excitability and seizures. 3 Simplistically and with due deference to some differing findings, 3 the prevailing view is that estradiol exerts direct excitatory effects at the neuronal membrane, where it augments NMDA-mediated excitatory neurotransmission. 4, 5 This enhances the resting discharge rates of neurons in a number of brain areas, including the hippocampus, 4 -6 where estradiol increases excitability of the hippocampal CA1 pyramidal neurons and induces repetitive firing in response to Schaffer collateral stimulation. 5 Estradiol potentiates neuronal excitability by regulating neuronal plasticity. It increases the density of spines and excitatory, NMDA receptor-containing synapses on apical dendrite branches of hippocampal CA1 pyramidal neurons via a post-transcriptional mechanism. 7, 8 The dendritic spine density on these neurons correlates positively with the levels of circulating estradiol during the estrous cycle of the rat and is decreased by oophorectomy. 7, 8 Over the course of 48 hours, however, estradiol restores inhibitory tone by increasing the density of GABA receptors. 9 The combination of enhanced sensitivity to excitatory input and the restoration of inhibitory input could result in a broader dynamic range of neuronal activity. 9 The com-bination of increased excitatory input and heightened firing threshold could increase synchrony of discharges, which is thought to be an important pathophysiologic mechanisms in the generation of seizures. Estradiol may affect neuronal excitability by cytosolic neuronal estrogen receptor-mediated, genomically dependent mechanisms. 2 Receptors are particularly abundant in the temporolimbic system, and especially in the medial and cortical amygdaloid nuclei; they occur in much fewer numbers in the hippocampal pyramidal cell layer and the subiculum. 10, 11 Estrogen receptor-containing neurons colocalize with other neurotransmitters, including GABA. 12, 13 By regulating the expression of genes affecting the activity, release, and postsynaptic action of different neurotransmitters and neuromodulators, estrogens may act to modulate the excitability of neurons which concentrate estradiol. For instance, estradiol can lessen inhibitory neurotransmission by decreasing GABA synthesis in the corticomedial amygdala by reducing the activity of glutamic acid decarboxylase, 14 and can enhance brain epileptogenic muscarinic neurotransmission by increasing choline acetyl transferase and acetylcholine. 15 In adult experimental animals, the thresholds of limbic seizures in female rats fluctuate during the estrus cycle inversely to serum estradiol levels. 16 Physiological doses of estradiol activate spike discharges 5, 6, 17, 18 and lower the thresholds of seizures induced by electroshock, kindling, pentylenetetrazol, kainic acid, ethyl chloride, and other agents and procedures. [17] [18] [19] [20] [21] [22] In rabbits, topical brain application, as well as intravenous systemic administration, of estradiol produces a significant increase in spontaneous electrically recorded paroxysmal spike discharges. 18 The increase is seen within a few seconds of application, which suggests a direct membrane rather than a genomic effect, and the increase is more dramatic in animals with pre-existent cortical lesions. 17, 18 The role of estrogen may be more complex, however; there is also evidence in some models that estradiol can raise seizure thresholds in the hippocampal region and provide neuroprotection against seizure-induced injury. 3 In a clinical setting, Logothetis et al. 23 showed that intravenously administered conjugated estrogen clearly activated epileptiform discharges in 11 of 16 women and was associated with clinical seizures in 4 of them. Postmenopausal hormonal supplement using conjugated estrogen and medroxyprogesterone has resulted in a doserelated increase in seizure frequency as well.
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Progesterone
Progesterone, and particularly some of its neuroactive metabolites, most notably allopregnanolone (AP), exerts direct membrane-mediated inhibitory effects by potentiating GABA A -mediated chloride conductance. 1, 25, 26 Most of the membrane effect of progesterone is due to the action of AP, the 3␣-hydroxylated (i.e., A-ring-reduced) metabolite, 3␣-hydroxy-5␣-pregnane-20-one. 1, 26 Both AP and the 3,5-hydroxylated natural metabolite of the mineralocorticoid deoxycorticosterone, allotetrahydrodeoxycorticosterone (allo-THDOC), are among the most potent of a number of endogenous neuroactive steroids with a direct membrane effect on neuronal excitability. 1, 25, 26 Allopregnanolone, but not allo-THDOC, is devoid of hormonal effects and may, together with other related neuroactive steroids, be thought of as an endogenous regulator of brain excitability with anxiolytic, sedative and hypnotic, and anticonvulsant properties. 1, 25, 26 Both AP and allo-THDOC hyperpolarize hippocampal and other neurons by potentiating GABA A -mediated inhibition. 1, 26 At physiological (nanomolar) levels they interact with an extrasynaptic steroid-specific site near the synaptic receptor to facilitate chloride channel opening and prolong the inhibitory action of GABA on neurons. 1, 25, 26, [22] [23] [24] [25] [26] [27] [28] At higher pharmacological (micromolar) concentrations, AP also has a direct effect at the synaptic GABA A receptor to induce chloride currents. 1, 26 Allopregnanolone is one of the most potent ligands of GABA A receptors in the CNS, with affinities similar to those of the potent benzodiazepine flunitrazepam and approximately a thousand times higher than those of pentobarbital. 1, 25 The parent steroid, progesterone, enhances GABA-induced chloride currents only weakly and only in high concentrations. 1, 28 Plasma and brain levels of AP parallel those of progesterone in rats. In women, plasma levels of AP correlate with progesterone levels during the menstrual cycle and in pregnancy. 1 Brain activity of progesterone and AP is not dependent solely on ovarian and adrenal production, however, because both progesterone and AP are synthesized de novo in the brain. 29 Their synthesis is region specific and includes the cortex and the hippocampus. 29 By contrast, allo-THDOC is synthesized only by the adrenal gland and not in the brain. Allopregnanolone, allo-THDOC, and a number of other endogenous and synthetic pregnane steroids have a potent anticonvulsant effect in bicuculline-, metrazol-, picrotoxin-, pentylenetetrazol-, pilocarpine-, and kainic acid-induced seizures and against status epilepticus, but are ineffective against electroshock-and strychnine-induced seizures. 25,30 -33 Allopregnanolone is an effective anticonvulsant against the secondarily generalized component of the seizure, but not against the amygdala focal discharge. 34 The antiseizure effect of progesterone in progesterone receptor knockout (PRKO) mice is blocked by the reductase inhibitor finasteride, which blocks the conversion of progesterone to AP. 35 The anticonvulsant properties of AP resemble those of the benzodiazepine, clonazepam. 13, 25, 32 Although AP is less potent than clonazepam, it may have lower relative toxicity. 31, 32 The anticonvulsant effect of AP is greater in female rats in the diestrus 1 part of the ovulatory cycle (equivalent to human mid-luteal phase, when progesterone levels are high) than in estrus (equivalent to ovulation, when estrogen levels are high) or in the male. 27 Enhanced mid-luteal efficacy at the GABA A receptor may be related to a progesterone-induced enhanced formation of the ␦ GABA A receptor subtype. 36 Rapid withdrawal of progesterone in late diestrus makes the GABAA receptor insensitive to benzodiazepine, but not AP, perhaps as the result of a decrease in the benzodiazepine sensitive synaptic GABAA receptors. 32 This effect can be blocked by inhibiting the formation of the ␣4 subunit of the GABAA receptor. 32, 27 By contrast, some of the sulfated neuroactive steroids have excitatory neuronal effects. They include pregnenolone sulfate and dehydroepiandrosterone sulfate (DHEAS), which is the naturally occurring sulfated esters of the progesterone precursor pregnenolone and progesterone metabolite DHEA. 1 They increase neuronal firing when directly applied to neurons by negatively modulating the GABA A receptor 1 and by facilitating glutamate-induced excitation at the NMDA receptor. 37 In animal seizure models, pregnenolone sulfate and DHEAS have proconvulsant effect. 38 Of note, serum DHEAS levels are substantially reduced by enzyme-inducing antiepileptic drugs such as phenytoin and carbamazepine. 39, 40 Progesterone also potentiates the action of the powerful endogenous inhibitory substance adenosine. 41 Progesterone itself also substantially diminishes nicotinic acetylcholine receptor-mediated conductance, which may be relevant to autosomal dominant nocturnal frontal lobe epilepsy. 42 Progesterone may act via genomic mechanisms to influence the enzymatic activity controlling the synthesis and release of various neurotransmitters and neuromodulators produced by progesterone receptor-containing neurons. 12 Progesterone binds specific cytosolic receptors not only to produce its own characteristic reproductive effects, but also to lower estrogen receptor numbers and thereby antagonize estrogen actions. 43 Chronic progesterone decreases the number of hippocampal CA1 dendritic spines and excitatory synapses faster than the simple withdrawal of estrogen, counteracting the stimulatory effects of estradiol. 8 Progesterone and AP have also been shown to have neuroprotective effects on hippocampal neurons in kainic acid-induced seizure models. 44 In most adult female animal models, progesterone depresses neuronal firing, 45 lessens spontaneous and induced epileptiform discharges, 20 -22,44 -46 and retards kindling and decreases seizure occurrence. 20 -22,44 -46 Hoffman et al. 47 concluded that their findings in rat models are consistent with the hypothesis that progesterone produces its effects by reducing seizures, whereas estrogen has little beneficial effect on seizure behavior but protects the hippocampus from the damage that seizures produce. Bäckström et al. 48 found that intravenous infusion of progesterone sufficient to produce luteal phase serum levels was associated with a significant decrease in interictal spike frequency in four of seven women with partial epilepsy. (For results of clinical treatment trials using progestogens, see below.)
DEFINITION, PATTERNS AND PREVALENCE
Seizures do not occur randomly in the majority of men and women with epilepsy. 49, 50 In more than 50% of cases, they tend to cluster. 49, 50 Seizure clusters, in turn, may occur with temporal rhythmicity in a significant proportion of men (29%) and women (35%) with epilepsy (FIG. 2) . 3, [51] [52] [53] [54] When the periodicity of seizure exacerbation aligns with the menstrual cycle, it is commonly known as catamenial epilepsy. 52 This may be attributable to 1) the neuroactive properties of steroid hormones and 2) the cyclic variation in their serum levels. 52 Physiological endocrine secretion during the menstrual cycle influences the occurrence of seizures (FIG. 2) . In ovulatory cycles, seizure frequency shows a statistically significant positive correlation with the serum estradiol/ progesterone ratio. 55 This ratio is highest during the days prior to ovulation and menstruation and is lowest during the early and mid-luteal phase. 55 The premenstrual exacerbation of seizures has been attributed to the rapid withdrawal of the antiseizure effects of progesterone. 54, 55 Mid-cycle exacerbations may be due to the preovulatory surge of estrogen, unaccompanied by any rise in progesterone until ovulation occurs. 54 -56 Seizures are least common during the mid-luteal phase when progesterone levels are highest, 54 -56 except in anovulatory cycles, in which case the mid-cycle surge in estrogen still occurs (albeit not as high as in ovulatory cycles) but is not accompanied by any substantial increase in progesterone levels. 52 Herzog et al. 52, 53 presented statistical evidence to support the concept of catamenial epilepsy and the existence of at least three distinct patterns of seizure exacerbation in relation to the menstrual cycle (FIG. 1): 1) perimenstrual (C1: day Ϫ3 to 3) and 2) periovulatory (C2: day 10 to Ϫ13) in ovulatory cycles, and 3) luteal (C3: day 10 to 3) in anovulatory or inadequate luteal phase cycles. In these cycles, day 1 is the first day of menstrual flow and ovulation is presumed to occur 14 days before the subsequent onset of menses (day Ϫ14). These three patterns can be demonstrated simply by first charting menses and seizures and then obtaining a midluteal phase serum progesterone level to distinguish between normal and inadequate luteal phase cycles (Ͻ5 ng/mL). One subsequent investigation has suggested that the C1 and C2 catamenial patterns show high sensitivity and specificity
FIG. 2.
Three patterns of catamenial epilepsy: perimenstrual (C1) and periovulatory (C2) exacerbations during normal ovulatory cycles and entire second half of the cycle (C3) exacerbation during inadequate luteal phase cycles, where day 1 is the first day of menstrual flow and day Ϫ14 is the day of ovulation. E2 ϭ estradiol, g/mL; F ϭ follicular phase; O ϭ ovulatory phase; L ϭ luteal phase; M ϭ menstrual phase; P ϭ progesterone, ng/mL.
for occurrence in ovulatory cycles, whereas the C3 pattern shows high sensitivity but only moderate specificity for occurrence during anovulatory cycles, occurring also in ovulatory cycles in which the mid-luteal estradiol/ progesterone ratio was high. 57 Although the precise definition of catamenial epilepsy remains arbitrary, one may maximize the efficiency of distinguishing between women whose seizure occurrence shows a high versus a low degree of hormonal sensitivity by using the points of inflection of the Sshaped distribution curves that define the relationship between the severity of seizure exacerbation and the number of women who have exacerbation. 52, 53 These points are calculated to be in the vicinity of a twofold increase in average daily seizure frequency during the phases of exacerbation, relative to the baseline phases, for all three types of catamenial exacerbation. We propose the use of these points of inflection values in seizure frequency for the designation of catamenial epilepsy. By this criterion, approximately one third of women with intractable partial epilepsy would qualify for the designation of having catamenial epilepsy. 52, 53 Adoption of a standard (albeit arbitrary) nomenclature may provide greater uniformity in study designs for the investigation of the pathogenesis and treatment of catamenial seizure exacerbation.
HORMONAL TREATMENT
Progestogen therapy
The term progestogen refers to the broad class of progestational agents. These include progesterone (i.e., naturally occurring progesterone) and progestins (i.e., synthetic progestational agents). Progestogen treatment (Tables 1 and 2 ) has taken two forms: 1) cyclic progesterone therapy that supplements progesterone during the luteal phase and withdraws it gradually premenstrually and 2) suppressive therapy, in which the goal is to suppress the menstrual cycle (generally accomplished using injectable progestins or long-acting, gonadotropin releasing-hormone analogs) ( Table 1) .
Cyclic progesterone therapy
In contrast to published reports of cyclic oral progestin investigations that have not been shown to have efficacy in producing significant reductions in seizure frequency, 58, 59 two open-label trials of adjunctive progesterone therapy for women with catamenial epilepsy have documented substantial and statistically significant reductions in seizure occurrence (Table 2) . 60, 61 In one investigation of women who had inadequate luteal phase cycles with catamenial exacerbation of intractable complex partial seizures, 6 of 8 women experienced improved seizure control, with a 68% decline in average monthly seizure frequency over 3 months for the whole group. 60 In a subsequent openlabel trial of adjunctive cyclic progesterone versus the optimal antiseizure medication alone in 25 women with perimenstrual catamenial seizure exacerbation (14 with anovulatory cycles and 11 with ovulatory cycles), 18 of the women (72%) experienced fewer seizures, with an overall average monthly decline of 54% for complex partial and 58% for secondary generalized seizures over 3 months. 61 Progesterone was more efficacious when administered during the entire second half of the cycle, rather than just premenstrually, and then tapered and discontinued gradually over 3 or 4 days at the end of the cycle. 61 Failure to taper gradually premenstrually can result in rebound seizure exacerbation.
At 3 years, 15 of the 18 women who had fewer seizures remained on both cyclic progesterone therapy and their original antiepileptic drugs continued to show improved seizure control, compared with their own baseline ( Table 2) . 62 Three women were entirely seizure free, four had total seizure reductions of 75% to 99%, and eight had reductions of 50% to 74%. Complex partial seizures in these 15 women were lower by a statistically significant 62%; secondary generalized motor seizures were reduced by a statistically significant 74%. Antiepileptic drug serum levels did not show any significant change between treatment and baseline values. The three remaining women who continued on progesterone therapy had 10% to 50% improvement at the end of the original investigation at 3 months; they were not considered further for this analysis because they changed antiepileptic drugs.
By way of critique, the weakness of these preliminary progesterone investigations is that they were not placebocontrolled or blinded. The favorable 3-year follow-up results are biased by analysis of only 15 of the original 25 subjects. These 15 who remained on the original treatment regimen are more likely to represent those who had the most favorable response. Nonetheless, there are reasons why the results of the present investigation may represent more than placebo effects. First, few placebo studies (including our own oral synthetic progestin trial that used a similar methodology, and could be used, therefore, as a retrospective control), show favorable response in more than 50% of subjects. Second, few placebo treatments have resulted in greater than 50% seizure reduction. Third, although placebo effects generally wear off over a few months, substantial and statistically significant improvements in the present investigation persisted after 3 years in the majority of subjects. 62 Another argument against the placebo explanation is that the beneficial effect of progesterone can be eliminated by the concomitant use of a reductase inhibitor, which presumably blocks the reduction of progesterone to its potent GABAergic metabolite AP. 63 Finally, there is transcranial magnetic stimulation evidence that progesterone may increase inhibition in the brain premenstrually. 64 A prospective multicenter, randomized, double-blind, placebo-controlled investigation of cyclic, adjunctive progesterone therapy in the management of women with catamenially exacerbated, intractable localization related epilepsy is now under way. 50, 53, 57 Natural progesterone is available as an extract of soy or yams in lozenge form in various dosages ranging from 25 mg to 200 mg. and should be administered three times daily because of its brief half-life of approximately 4 to 6 hours. 60 -62 The daily regimen to achieve physiological luteal range serum levels measured 4 hours after administration ranges from 50 mg to 200 mg, taken three times daily, with the usual optimal daily dose ranging from 300 mg to 600 mg. 60 -62 The maintenance dosage and regimen should be individualized, based on a combination of clinical response and serum progesterone levels between 20 and 40 ng/mL. Progesterone is also available in micronized form in an oral caplet preparation that may also exert similar antiseizure effects, although formal investigations to this effect are lacking. Theoretically, it is possible that first pass through the liver using the oral micronized form may result in the delivery of different concentrations of progesterone and its neuroactive metabolite to the brain.
The most common adverse effects include sedation, emotional depression, and asthenia. 60 -62 Progesterone use may also occasionally be associated with breast tenderness, weight gain, and irregular vaginal bleeding, and sometimes constipation. Discontinuation of the hormone or lowering of the dosage resolves these adverse effects. 60 -62 Drug interactions are an important consideration. Higher progesterone dosages may be required to achieve luteal range levels in women who take antiseizure medications because carbamazepine, phenytoin, and barbiturates are known to enhance the hepatic metabolism of gonadal and adrenal steroid hormones as well as to increase hormonal binding to serum proteins. 63 Progesterone use has been associated with changes in antiseizure medication levels in some cases, but this effect has been sporadic and has not occurred in a predictable direction. It may be advisable, therefore, to check serum antiseizure medication levels during the initiation of concomitant hormonal therapy.
Progestin therapy
Parenteral depomedroxyprogesterone may lower seizure frequency when it is given in sufficient dosage to induce amenorrhea. 59, 65 In one open-label study of 14 women with refractory partial seizures and normal ovulatory cycles, parenteral depomedroxyprogesterone administration in doses large enough to induce amenorrhea (i.e., 120 -150 mg every 6 -12 weeks) resulted in a 39% seizure reduction. 59 It was unclear whether the effect was due to direct anticonvulsant activity of medroxyprogesterone or to the hormonal consequences of the induced amenorrhea. One patient, who had absence rather than partial seizures, did not improve. Adverse effects included those encountered with natural progesterone. Depot administration, however, is also commonly associated with hot flashes, irregular breakthrough vaginal bleeding, and a lengthy delay of 6 to 12 months in the return of regular ovulatory cycles. 59 Long-term hypoestrogenic effects on cardiovascular and emotional status, as well as headache, need to be considered with chronic use. Bone density is only partially maintained.
Oral synthetic progestins administered cyclically or continuously have not proven to be an effective therapy for seizures in clinical investigations, 58, 59 although individual successes with continuous daily oral use of norethisterone and combination pills have been reported. 66 
Gonadotrophin-releasing hormone analog therapy
Bauer et al. 67 used triptorelin, a synthetic gonadotrophin-releasing hormone (GnRH) analog (3.75 mg) in a controlled-release depot form intramuscularly every 4 weeks for an average of 11.8 months in 10 women (aged 20 -50) with catamenial seizures intractable to high therapeutic doses of carbamazepine, diphenylhydantoin, phenobarbital, and valproic acid in monotherapy or combination. They remained on a stable dose of the anticonvulsant throughout the period of treatment with triptorelin. Three patients became seizure free, and four showed a decrease in seizure frequency of up to 50%. In one the duration of seizures was shortened, and in two there was no therapeutic effect. These results were attained within the first 2 months of starting triptorelin. The study was not a controlled study, and longer term follow-up was not available for some of the patients. Serum luteinizing hormone and estrogen were measured in one patient before and during the 2nd month of triptorelin treatment; and as expected showed marked inhibition of luteinizing hormone and estrogen production. All 10 women became amenorrheic, and 8 of them experienced hot flashes, headache, or weight gain.
Haider and Barnett 68 reported on their use of goserelin 3.6 mg subcutaneously every 4 weeks in a 41-year-old woman who had had frequent catamenial status epilepticus despite therapeutic anticonvulsant drug levels which also did not respond to levonorgestrel-ethinyl estradiol. They reported a decrease in frequency from 10 admissions for status epilepticus to 3 over a similar period.
The GnRH analogs basically create a medical oophorectomy. Common adverse effects are flushing, vaginal dryness, and dyspareunia. Serious long-term risks include osteoporosis and cardiovascular disease. Reid and Gangar 69 suggested the addition of medroxyprogesterone acetate and conjugated estrogens to goserelin to prevent this while still abolishing most of the cyclical fluctuations of ovarian hormones. Finkelstein et al. 70 recently discussed the use of parathyroid hormone to prevent bone loss in women treated with GnRH analogs. Although neither Bauer et al. 67 nor Haider and Barnett 68 reported exacerbation of seizures with GnRH analogs, we have found that during the first 3 weeks, when there is an initial stimulation of ovarian estradiol production before it is inhibited, women may experience a marked exacerbation of their seizures. 36, 71 
